I-Mab BioPharma of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. Ocumens …
( read original story …)
The Shanghai News
I-Mab BioPharma of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. Ocumens …
( read original story …)